A 104-WEEK DELAYED-START ANALYSIS OF PASADENA (PHASE II STUDY EVALUATING THE SAFETY AND EFFICACY OF PRASINEZUMAB IN EARLY PARKINSON'S DISEASE)
Currently available treatments for PD have powerful effects on symptoms but do not prevent or slow disease progression. Prasinezumab is a humanised monoclonal antibody designed to target aggregated α-synuclein and slow PD progression. This study (PASADENA), a multicentre, randomised, double-blind, placebo-controlled study, aimed to evaluate the safety and efficacy of prasinezumab in individuals with early Parkinson’s disease.